2026-03-27 01:43Financial Performance - In 2025, the company achieved a revenue of 19.30 billion CNY, a year-on-year increase of 11.97%, accounting for 16.06% of total revenue [5] - The cash dividend distribution plan for 2025 is 14.30 CNY per share (before tax), totaling approximately 1.27 billion CNY [21] Innovation and Product Development - The company has 40 projects in the pipeline, with 12 in the application stage and 4 in Phase III clinical trials [6] - Key products expected to be approved in 2026 include: - Lakanqita monoclonal antibody for psoriasis [6] - Recombinant human follicle-stimulating hormone injection [6] - P-CAB class innovative drug JP-1366 for gastroesophageal reflux disease [6] Market Expansion and Internationalization - The international revenue reached 19.30 billion CNY in 2025, with a growth of 11.97% [5] - The company is focusing on a systematic overseas layout, moving from simple product trade to localized operations [5] - The acquisition of Imexpharm Corporation in Vietnam is expected to enhance market access in Southeast Asia [20] Core Product Highlights - Lakanqita monoclonal antibody is positioned as the first IL-17A/F dual-target inhibitor in China, with a PASI100 response rate of 49.5% in clinical trials [6] - Aripiprazole microspheres (Alivai®) are the first long-acting formulation for schizophrenia in China, included in the national medical insurance directory [8] - Recombinant human follicle-stimulating hormone injection is expected to capture over 90% of the market in assisted reproduction [11] Clinical Development and Pipeline - NS-041, a candidate for epilepsy and depression, is in Phase II clinical trials, showing best-in-class potential [13] - The company has a complete ecosystem for microsphere products, with three successful launches and ongoing development of additional formulations [10] Strategic Focus Areas - The company aims to strengthen its position in chronic disease management, particularly in autoimmune and metabolic diseases [7] - The focus on AI-driven drug development is expected to enhance research capabilities and expedite the drug discovery process [19] Competitive Advantages - The company has established a robust sales network and marketing strategy, particularly in the psychiatric and reproductive health sectors [10] - The integration of CMC (Chemistry, Manufacturing, and Controls) capabilities is a key differentiator in the global market [19]